v3.24.1.u1
Segment Information
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)20242023
Immunology
HumiraUnited States$1,771 $2,948 
International499 593 
Total$2,270 $3,541 
SkyriziUnited States$1,656 $1,139 
International352 221 
Total$2,008 $1,360 
RinvoqUnited States$725 $449 
International368 237 
Total$1,093 $686 
Oncology
ImbruvicaUnited States$610 $638 
Collaboration revenues228 240 
Total$838 $878 
VenclextaUnited States$281 $265 
International333 273 
Total$614 $538 
Elahere(a)
United States
$64 $— 
EpkinlyCollaboration Revenues$22 $— 
International5 — 
Total$27 $— 
Aesthetics
Botox CosmeticUnited States$389 $409 
International244 250 
Total$633 $659 
Juvederm CollectionUnited States$106 $122 
International191 233 
Total$297 $355 
Other AestheticsUnited States$281 $246 
International38 40 
Total$319 $286 
Neuroscience
Botox TherapeuticUnited States$611 $587 
International137 132 
Total$748 $719 
VraylarUnited States$692 $560 
International2 1 
Total$694 $561 
Three months ended
March 31,
(in millions)20242023
DuodopaUnited States$25 $25 
International90 93 
Total$115 $118 
UbrelvyUnited States$197 $150 
International6 2 
Total$203 $152 
QuliptaUnited States$128 $66 
International3 — 
Total$131 $66 
Other NeuroscienceUnited States$61 $75 
International13 4 
Total$74 $79 
Eye Care
OzurdexUnited States$34 $39 
International97 76 
Total131 115 
Lumigan/GanfortUnited States$29 $63 
International62 67 
Total$91 $130 
Alphagan/CombiganUnited States$15 $28 
International44 43 
Total$59 $71 
RestasisUnited States$44 $79 
International13 13 
Total$57 $92 
Other Eye CareUnited States$105 $110 
International95 90 
Total$200 $200 
Other Key Products
MavyretUnited States$144 $171 
International205 193 
Total$349 $364 
CreonUnited States$285 $305 
Linzess/ConstellaUnited States$257 $251 
International9 8 
Total$266 $259 
All other$744 $691 
Total net revenues$12,310 $12,225 
(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.